Production
By keeping up with trends in the pharmaceutical industry, JGL boasts a flexible and modern production, compliant with regulatory (GMP) and internal quality demands.
Since targeted investment into modern technological processes is
the basis for an efficient, quality product, the production
capacities within JGL are constantly modernized and expanded as
part of continuous investments.
Since 2002, when the sterile solution production plant and the
new raw material storage facility were opened, production
capacities expanded with the plant for solid oral forms,
quality-control laboratory, microbiological laboratory and in 2009
with a modern plant for semi-solid pharmaceutical forms, conforming
to EU GMP standards. The newest investment into capacities for
sterile pharmaceutical forms - a new production plant for sterile
solutions and a control and analysis laboratory - was completed by
the end of September 2011. The new production line is designed
exclusively for mechanical pump sprays which separate this
production from the production of other, existing sterile forms.
The investment increased the production capacity by an additional
20 million units, which means that the total company volume was
increased to 38 million units of sterile solutions in the form of
sprays and drops.
Whether developing a new product or improving the features of an
existing one, our experts have been developing and manufacturing
the following pharmaceutical forms:
- sterile solutions (eye drops, sprays and
nose drops)
- solid oral forms (capsules and
tablets)
- semi-solid forms (ointments, creams and
gels)
- solutions (syrups, herbal
drops)
- dermatological solutions